Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares ZUG, Switzerland and BOSTON, USA

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

ZUG, Switzerland and BOSTON, USA, May 31, 2023 Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save

sight and improve eye care, today announced the pricing of a follow-on public offering of 3,500,000 ordinary shares at a public offering price of $11.50 per ordinary share, for gross proceeds of approximately

$40.25 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Oculis has granted the underwriters a 30-day option to purchase up to an additional 525,000 ordinary

shares on the same terms and conditions. The offering is expected to close on or about June 5, 2023, subject to satisfaction of customary closing conditions.

Oculis intends to use the net proceeds from this offering, together with its existing resources, to advance its development programs in Diabetic Macular Edema

and other ophthalmic indications, and for working capital and general corporate purposes.

BofA Securities and SVB Securities are acting as joint

book-running managers for this offering. Wedbush PacGrow, Baird, H.C. Wainwright & Co. and Pareto Securities are acting as co-managers for the offering. Arctica Finance is acting as financial advisor

A registration statement on Form F-1 (File

No. 333-272256) relating to the securities referred to herein has been filed with the U.S. Securities and Exchange Commission ( SEC ) and was declared effective by the SEC on May 31, 2023.

The securities referred to in this press release will be offered in the United States only by means of a prospectus. Copies of the final prospectus related to this offering may be obtained, when available, from: BofA Securities, Attention:

Prospectus Department, NC1-022-02-25, 201 North Tryon, Charlotte, North Carolina 28255-0001, or by email

at dg.prospectus_requests@bofa.com or SVB Securities, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, Telephone: 1-800-808-7525, ext. 6105, Email: syndicate@svbsecurities.com. Investors may also obtain these documents at no cost by visiting the SEC s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these

securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Oculis (Nasdaq: OCS) is a global

biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet medical need.

It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye

drops, a topical biologic candidate in Phase 2b development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders,

such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept

trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the United States, Europe and China, Oculis goal is to deliver life-changing eye treatments to

patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

Consilium Strategic Communications

Amber Fennell, Tracy Cheung, David Daley

Cautionary Note Regarding

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform

Act of 1995, including with respect to the use of proceeds and timing and consummation of the offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that are described in the Risk

Factors sections of the final prospectus for such offering to be filed with the SEC, any of which could cause the events and circumstances discussed in such forward-looking statements to not occur on the terms described or at all. Prospective

investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Oculis undertakes no obligation to update any such forward-looking statements after the date hereof, except as required